CL
CLABF.US Core One Labs Inc
- Market cap
- USD 470.00
- P/E
- -
- P/B
- 0.21x
- ROE
- -58.4%
- Dividend yield
- -
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 3 quarters up to Dec 2023.
Is CLABF.US undervalued?
Graham numberThe Graham number of Core One Labs Inc cannot be estimated reliably (it needs positive earnings and book value).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
Core One Labs Inc fundamental analysis
No fundamental analysis for Core One Labs Inc yet.
Core One Labs Inc stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About Core One Labs Inc
Core One Labs Inc. operates as a psychedelic research and development company. The company focuses on providing psychedelic medicines to novel delivery systems and psychedelic assisted psychotherapy; and intends to further develop and apply the technology to psychedelic compounds, such as psilocybin. It also provides natural health products; news dissemination services; financing services; and operates medical clinics, as well as engages in micro cultivation. The company was…
Full company profileCore One Labs Inc financial statements
2023 annualized: Fiscal year 2023 is not finished. Income statement and cash flow are annualized from 3 quarters up to Dec 31, 2023, the balance sheet is the latest quarter. Figures change when the annual report is published.
Core One Labs Inc annual financial statements (CAD; K = thousand, M = million, B = billion, T = trillion)
| Item | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2023 Anlz |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | |||||||||||
| Revenue | - | - | 58.3K | 56.1K | 191K | 4.08M | 5.04M | 2.91M | 432K | 459K | 342K |
| Gross Profit | - | - | 56.7K | 56.1K | 191K | -1.69M | -670K | 289K | 393K | 416K | 317K |
| Operating Income | -492K | -430K | -1.07M | -1.94M | -13.0M | -11.9M | -15.3M | -6.52M | -12.2M | -7.84M | -2.74M |
| EBITDA | -344K | -282K | -931K | -1.75M | -13.0M | -11.9M | -9.25M | 1.90M | -12.1M | -7.80M | -3.25M |
| Net Income | -442K | -428K | -1.21M | -2.87M | -12.6M | -12.3M | -21.5M | -54.6M | -37.1M | -16.0M | -3.29M |
| EPS | -14 | -12 | -7.79 | -8.71 | -18 | -11 | -15 | -10 | -2.57 | -0.49 | -0.07 |
| Balance Sheet | |||||||||||
| Total Assets | 70.0K | 392K | 1.43M | 1.67M | 13.1M | 21.1M | 17.8M | 9.52M | 7.61M | 8.11M | 7.40M |
| Total Liabilities | 1.71K | 402K | 376K | 254K | 2.24M | 4.78M | 12.2M | 4.13M | 3.30M | 1.40M | 1.76M |
| Shareholders' Equity | 68.3K | -9.64K | 1.06M | 1.42M | 11.4M | 17.8M | 7.23M | 5.39M | 4.31M | 6.72M | 5.64M |
| Cash & Short-term Investments | 55.6K | 201K | 119K | 440K | 2.75M | 994K | 412K | 1.90M | 873K | 736K | 155K |
| Total Debt | - | 104K | - | - | 655K | 721K | 4.37M | 428K | 30.0K | - | 250K |
| Cash Flow | |||||||||||
| Operating Cash Flow | -294K | -49.3K | -1.01M | -1.49M | -5.21M | -10.2M | -5.77M | -2.32M | -4.64M | -2.77M | -914K |
| Capital Expenditure | 9.60K | 0.00 | 141K | 594K | 7.81M | 6.68M | 1.64M | 8.68K | 8.68K | 33.6K | 0.00 |
| Free Cash Flow | -304K | -49.3K | -1.15M | -2.09M | -13.0M | -16.8M | -7.41M | -2.32M | -4.65M | -2.80M | -914K |
| Ratios | |||||||||||
| ROE | -646.7% | - | -114.1% | -202.4% | -110.2% | -69.1% | -296.9% | -1,012.8% | -860.0% | -238.0% | -58.4% |
| ROA | -630.9% | -109.2% | -84.2% | -171.7% | -95.9% | -58.3% | -120.6% | -573.5% | -486.9% | -197.0% | -44.5% |
| Net Profit Margin | - | - | -2,069.8% | -5,110.6% | -6,590.6% | -301.1% | -425.7% | -1,874.6% | -8,585.2% | -3,485.4% | -963.6% |
| Debt to Equity | - | - | - | - | 0.06x | 0.04x | 0.60x | 0.08x | 0.01x | - | 0.04x |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Total Debt
- Short and long-term borrowings.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
- Debt to Equity
- Total debt divided by shareholders' equity.
Core One Labs Inc dividends
Core One Labs Inc has not paid dividends in the last 9 fiscal years.
Last stock split: 1:8 on Jul 15, 2021.
Who owns Core One Labs Inc
Ownership data of Core One Labs Inc is not available yet.
Core One Labs Inc company profile
- Company name
- Core One Labs Inc
- Ticker
- CLABF.US
- Exchange
- USA Stocks
- Sector
- Healthcare
- Industry
- Biotechnology
- Fiscal year end
- March
- Address
- 1199 West Hastings Street, Vancouver, BC, Canada, V6E 3T5
- Phone
- 888 452 6731
- Website
- core1labs.com
About Core One Labs Inc
Core One Labs Inc. operates as a psychedelic research and development company. The company focuses on providing psychedelic medicines to novel delivery systems and psychedelic assisted psychotherapy; and intends to further develop and apply the technology to psychedelic compounds, such as psilocybin. It also provides natural health products; news dissemination services; financing services; and operates medical clinics, as well as engages in micro cultivation. The company was formerly known as Lifestyle Delivery Systems Inc. and changed its name to Core One Labs Inc. in September 2019. Core One Labs Inc. was incorporated in 2010 and is headquartered in Vancouver, Canada.
Core One Labs Inc management
6- Mr. Joel ShackerCEO & Director · born 1991
- Mr. Geoffrey BaldersonCFO, Secretary & Director · born 1978
- Dr. Santiago FerroChief Medical Officer & Director
- Mr. Brad Paul EckenweilerFounder & Advisor · born 1954
- Dr. Jan Burian Ph.D.Chief Technical Officer
- Dr. Elizabeth MatthewsHead of Scientific & Regulatory Affairs